Becton Dickinson ROA 2010-2024 | BDX
Current and historical return on assets (ROA) values for Becton Dickinson (BDX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Becton Dickinson ROA - Return on Assets Historical Data |
Date |
TTM Net Income |
Total Assets |
Return on Assets |
2024-06-30 |
$1.41B |
$55.58B |
2.63% |
2024-03-31 |
$1.32B |
$54.16B |
2.48% |
2023-12-31 |
$1.22B |
$52.27B |
2.29% |
2023-09-30 |
$1.42B |
$52.78B |
2.67% |
2023-06-30 |
$1.58B |
$53.02B |
2.96% |
2023-03-31 |
$1.53B |
$54.39B |
2.86% |
2022-12-31 |
$1.52B |
$53.13B |
2.84% |
2022-09-30 |
$1.69B |
$52.93B |
3.15% |
2022-06-30 |
$1.67B |
$53.20B |
3.10% |
2022-03-31 |
$1.83B |
$54.79B |
3.38% |
2021-12-31 |
$1.68B |
$53.36B |
3.10% |
2021-09-30 |
$2.00B |
$53.87B |
3.68% |
2021-06-30 |
$1.87B |
$54.33B |
3.42% |
2021-03-31 |
$1.64B |
$54.92B |
3.01% |
2020-12-31 |
$1.51B |
$54.75B |
2.79% |
2020-09-30 |
$0.77B |
$54.01B |
1.44% |
2020-06-30 |
$0.79B |
$53.96B |
1.49% |
2020-03-31 |
$0.92B |
$53.52B |
1.76% |
2019-12-31 |
$0.76B |
$51.95B |
1.46% |
2019-09-30 |
$1.08B |
$51.77B |
2.07% |
2019-06-30 |
$0.78B |
$52.23B |
1.48% |
2019-03-31 |
$0.93B |
$52.60B |
1.74% |
2018-12-31 |
$0.90B |
$52.93B |
1.66% |
2018-09-30 |
$0.16B |
$53.90B |
0.29% |
2018-06-30 |
$0.62B |
$53.98B |
1.23% |
2018-03-31 |
$-0.10B |
$54.57B |
-0.22% |
2017-12-31 |
$0.29B |
$55.36B |
0.76% |
2017-09-30 |
$1.03B |
$37.73B |
3.34% |
2017-06-30 |
$0.76B |
$37.17B |
2.73% |
2017-03-31 |
$1.32B |
$24.12B |
5.26% |
2016-12-31 |
$1.31B |
$24.32B |
5.13% |
2016-09-30 |
$0.98B |
$25.59B |
3.76% |
2016-06-30 |
$1.14B |
$26.02B |
4.34% |
2016-03-31 |
$0.81B |
$26.24B |
3.06% |
2015-12-31 |
$0.69B |
$26.05B |
2.55% |
2015-09-30 |
$0.70B |
$26.48B |
2.77% |
2015-06-30 |
$0.82B |
$27.08B |
3.78% |
2015-03-31 |
$1.08B |
$28.29B |
6.03% |
2014-12-31 |
$1.15B |
$18.50B |
8.28% |
2014-09-30 |
$1.19B |
$12.45B |
9.65% |
2014-06-30 |
$0.97B |
$12.37B |
7.98% |
2014-03-31 |
$0.95B |
$12.25B |
7.91% |
2013-12-31 |
$0.94B |
$12.04B |
7.92% |
2013-09-30 |
$1.29B |
$12.15B |
11.01% |
2013-06-30 |
$1.49B |
$11.59B |
12.92% |
2013-03-31 |
$1.52B |
$11.63B |
13.29% |
2012-12-31 |
$1.53B |
$11.63B |
13.55% |
2012-09-30 |
$1.17B |
$11.36B |
10.40% |
2012-06-30 |
$1.18B |
$11.03B |
10.72% |
2012-03-31 |
$1.20B |
$11.20B |
10.97% |
2011-12-31 |
$1.22B |
$11.41B |
11.38% |
2011-09-30 |
$1.27B |
$10.43B |
12.26% |
2011-06-30 |
$1.37B |
$10.62B |
13.45% |
2011-03-31 |
$1.33B |
$10.34B |
13.63% |
2010-12-31 |
$1.32B |
$10.07B |
13.99% |
2010-09-30 |
$1.32B |
$9.65B |
14.36% |
2010-06-30 |
$1.24B |
$9.03B |
13.61% |
2010-03-31 |
$1.27B |
$8.94B |
14.06% |
2009-12-31 |
$1.24B |
$9.09B |
14.19% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical & Dental Supplies |
$69.388B |
$19.372B |
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|